Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo

Nature Medicine

Volumn 4, Issue 6, 1998, Pages 685-690

  Fueyo, J ^a   Gomez Manzano, C ^a   Yung, W K A ^a   Liu, T J ^a   Alemany, R ^b   Mcdonnell, T J ^a   Shi, X ^a   Rao, J S ^a   Levin, V A ^a   Kyritsis, A P ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR E2F;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ADENOVIRUSES, HUMAN; ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL DEATH; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; GLIOMA; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOGENE PROTEIN P21(RAS); RECOMBINANT FUSION PROTEINS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 0031749470     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0698-685     Document Type: Article

References (39)

1. Sherr, C.J. Cancer cell cycles. Science 274, 1672-1677 (1996).
2. Gomez-Manzano, C., Fueyo, J., Kyritsis, A.P. & Yung, W.K.A. in: Gene Transfer and Therapy for Neurological Disorders (eds. Chiocca, A.E. & Breakefield, X.) 201-225 (Human Press-Inc., Totowa, N.J., 1998).
3. Qin, X.Q. et al. The transcription factor E2F-1 is a downstream target of RB action. Mol. Cell. Biol. 15, 742-755 (1995).
4. Kovesdi, I., Reichel, R. & Nevins, J.R. Identification of a cellular transcription factor involved in E1A trans-activation. Cell 45, 219-228 (1986).
5. Helin, K. et al. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70, 337-350 (1992).
6. Kaelin, W.G. et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70, 351-364 (1992).
7. Shan, B. et al. Molecular cloning of cellular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F. Mol. Cell. Biol. 12, 5620-5631 (1992).
8. Johnson, D.C., Schwarz, J.K., Cress, W.D. & Nevins, J.R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365, 349-352 (1993).
9. Singh, P., Wong, S. H. & Hong, W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J. 13, 3329-3338 (1994).
10. Qin, X. Q., Livingston, D.M., Kaelin, W. G. & Adams, P.D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA 91, 10918-10922 (1994).
11. Wu, X. & Levine, A.J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 91, 3602-3606 (1994).
12. Field, S.J. et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85, 549-561 (1996).
13. Yamasaki, L. et al. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85, 537-548 (1996).
14. Gomez-Manzano, C. et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 56, 694-699 (1996).
15. Kyritsis, A.P., Xu, R., Bondy, M.L., Levin, V.A. & Bruner, J.M. Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol. Carcinog. 15, 1-4 (1996).
16. WAF1/Cip1 in human brain tumors. Oncogene 11, 2021-2028 (1995).
17. Gomez-Manzano, C. et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J. Natl. Cancer Inst. 14, 1036-1044 (1997).
18. Hunt, K.K. et al. Adenovirus-mediated expression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 57, 4722-4726 (1997).
19. Masuda, H., Miller, C., Koeffler, H.P., Battifora, H. & Cline, M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA. 84, 7716-7719 (1987).
20. Hirvonen, H.E. et al. Differential expression of myc, max and RB1 genes in human gliomas and glioma cell lines. Br. J. Cancer 69, 16-25 (1994).
21. Huang, J.-J. S. et al. Suppression of the neoplastic phenotype by replacement of the RB qene in human cancer cells. Science 242, 1563-1566 (1988).
22. Arap, W., Nishikawa, R., Furnari, F.B., Cavanee, W.K. & Huang, H.-J.S. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res. 55, 1351-1354 (1995).
23. Li, Y., Nichols, M.A., Shay, J.W. & Xiong, Y. Transcriptional repression of the D-type cyclin dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRB. Cancer Res. 54, 6078-6082 (1994).
24. Lukas, J., Petersen, B.O., Holm, K., Bartek, J. & Helin, K. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4-mediated growth suppression. Mol. Cell. Biol. 16, 1047-1057 (1996).
25. Hsieh, J.-K., Fredersdorf, S., Kouzarides, T., Martin, K. & Lu, X. E2F-1-induced apoptosis requires DNA binding by not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 11, 1840-1852 (1997).
26. Kyritsis, A.P. In Practice Guidelines for Neurologic Therapy (eds Lechtenberg, R. & Schutta, H.S.) 473-496 (Marcel Dekker, New-York, 1997).
27. Fueyo, J. et al. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12, 103-110 (1996).
28. Fueyo, J. et al. Suppression of human glioma growth by adenovirus mediated Rb qene transfer. Neurology (in the press).
29. Poluha, W. et al. The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol. Cell. Biol. 16, 1335-1341 (1996).
30. Polyak, K., Waldman, T., He, T.-C., Kinzler, K.W. & Vogelstein, B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10, 1945-1952 (1996).
31. Kuida, K. et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 384, 368-372 (1996).
32. Enari, M., Talanian, R.V., Wong, W.W. & Nagata, S. Sequential activation of ICE-like and CPP-32-like proteases during Fas-mediated apoptosis. Nature 380, 723-726 (1996)
33. Phillips, A.C., Bates, S., Ryan, K.M., Helin, K. & Vousden, K.H. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev. 11, 1853-1863 (1997).
34. Parr, M.J., et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nature Med. 3, 1145-1149 (1997).
35. Steck, P.A. et al. Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells. J. Cell Biochem. 32, 1-10 (1986).
36. Eastham, J.A. et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 55, 5151-5155 (1995).
37. Alemany, R. et al. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther. 3, 296-301 (1996).
38. Alemany, R. et al. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations. J. Virol. Methods 68, 147-159 (1997).
39. Attia, M.A. & Weiss, D.W. Immunology of spontaneous mammary carcinomas in mice. V: acquired tumor resistance and enhancement in strain of mice infected with mammary tumor virus. Cancer Res. 26, 1787-1800 (1996).